CJC-1295 vs HGH: how the two actually compare

Last updated 2026-07-26

What is the actual difference between CJC-1295 and HGH?

HGH (human growth hormone, the pharmaceutical version is called somatropin) is a 191-amino-acid protein that is structurally identical to the growth hormone your pituitary gland makes. When you inject it, you are adding finished hormone directly into your bloodstream. The FDA has approved recombinant somatropin products (Genotropin, Humatrope, Norditropin, and others) for specific diagnosed conditions like adult growth hormone deficiency and pediatric growth failure ^[1]. CJC-1295 is not growth hormone. It is a synthetic analogue of growth-hormone-releasing hormone (GHRH), the 44-amino-acid signal your hypothalamus sends to your pituitary to tell it to release GH. CJC-1295 binds the GHRH receptor and pushes the pituitary to secrete more of its own GH, in a pulsatile pattern that more closely mimics natural release than a flat exogenous dose does ^[2]. That mechanistic difference is the whole story. HGH bypasses your own regulatory system entirely. CJC-1295 works within it, meaning it only works if your pituitary is still capable of responding. In someone with a damaged or nonfunctional pituitary, CJC-1295 does little to nothing; HGH still works because it doesn't need the gland at all. For a full mechanism rundown, see our CJC-1295 overview.

Is CJC-1295 as strong as HGH at raising IGF-1?

Not in the way people assume. The original CJC-1295 (with DAC, the drug affinity complex version) was studied in a small human trial published in the Journal of Clinical Endocrinology & Metabolism. Multiple weekly doses (30 to 60 mcg/kg) produced dose-dependent increases in GH and IGF-1 that were sustained, with the paper reporting mean GH elevations lasting up to 6 days after a single dose at the top dose tested ^[3]. That is a real, measured pharmacodynamic effect. But it is not equivalent to the reliable, large, dose-titratable IGF-1 increases seen with direct somatropin therapy, where dosing is established well enough to be used clinically and monitored by IGF-1 lab draws in FDA-labeled treatment protocols ^[1]. CJC-1295 raises IGF-1 through a softer, self-limited mechanism, your own negative feedback loops (via somatostatin and IGF-1 itself) still cap how much GH gets released. HGH has no such brake once it's in your blood. Bodybuilding forums often claim CJC-1295 plus ipamorelin gives 'HGH-like' results at a fraction of the cost. That is folklore, not data. No published human trial has directly compared CJC-1295/ipamorelin combinations against therapeutic-dose recombinant HGH for body composition or performance outcomes. The comparison sounds intuitive but nobody has actually run it.

CJC-1295 with DAC vs without DAC: what's the difference and why does it matter here?

This distinction gets lost in casual conversation but it changes the comparison to HGH substantially. CJC-1295 with DAC has a drug affinity complex attached that lets it bind serum albumin, extending its half-life to roughly 6 to 8 days based on the pharmacokinetic data in the original Teichman et al. study ^[3]. That means one injection produces an elevated, sustained GH/IGF-1 profile for close to a week, the closest thing this molecule has to mimicking a steady, HGH-like elevation curve, though through pulsatile release rather than a flat exogenous level. CJC-1295 without DAC (also sold as 'Mod GRF 1-29') has a half-life measured in minutes, some sources cite under 30 minutes. It needs multiple daily injections to have a meaningful sustained effect, and its short action is exactly why it's frequently paired with a ghrelin-mimetic like ipamorelin, timed to hit right before a natural GH pulse (usually bedtime), rather than run as a background elevation like HGH therapy or DAC-CJC-1295. HGH injections themselves come in short-acting daily formulations and, more recently, weekly long-acting formulations (like Sogroya, approved by the FDA in 2020 for adult GH deficiency, dosed once weekly) ^[4]. So the DAC vs no-DAC split within CJC-1295 actually mirrors, in a rough way, the daily-vs-weekly split that already exists within FDA-approved HGH products. See our breakdown of CJC-1295 with DAC for the pharmacokinetics in more detail.

Is CJC-1295 legal and FDA-approved like HGH is?

No, and this is the sharpest practical difference between the two. Recombinant human growth hormone is FDA-approved, but only for specific labeled indications: adult growth hormone deficiency, Turner syndrome, chronic kidney disease in children, Prader-Willi syndrome, and a handful of other diagnosed conditions ^[1]. It is a prescription drug (distribution of human growth hormone is restricted under 21 U.S.C. 333(e), which sets criminal penalties for distribution without a valid prescription) that requires a diagnosis, a prescribing physician, and typically ongoing IGF-1 monitoring ^[5]. CJC-1295 has no FDA approval for any human use. It is not a legal dietary supplement either. It exists in a gray zone: often sold labeled 'for research use only, not for human consumption,' which is the actual language manufacturers use to stay outside FDA drug regulations while it's bought and self-administered off-label anyway. The FDA maintains a public warning letters database documenting enforcement actions against companies selling unapproved drugs, including peptides marketed with implied human dosing instructions ^[6]. That legal gap matters for sourcing quality control too. FDA-approved HGH products go through GMP manufacturing, batch testing, and cold-chain distribution requirements. Research-use CJC-1295 does not have to meet any of that by default, which is why third-party testing and provider-reviewed sourcing actually matters when a reader is choosing where to buy. See where to find CJC-1295 for sale for what to check before you order.

How do dosing and injection schedules compare?

Why is CJC-1295 usually paired with ipamorelin instead of used alone?

Ipamorelin is a ghrelin-receptor agonist (a GH secretagogue that works through a different receptor than CJC-1295). The rationale for stacking them is mechanistic, not folklore: GHRH analogues like CJC-1295 increase the amount of GH released per pulse, while ghrelin mimetics like ipamorelin increase the number and amplitude of pulses and also suppress somatostatin, the hormone that normally puts a brake on GH release ^[2]. Using both together, in theory, hits two separate points in the same pathway rather than saturating one. This is a real, published pharmacological principle: GHRH and ghrelin-mimetic secretagogues have been shown in separate lines of endocrine research to produce a synergistic rise in GH release when combined, compared to either alone, going back to older GHRP/GHRH combination studies in the 1990s literature on growth hormone secretagogues. What has not been shown is that this combination produces outcomes equivalent to, or better than, therapeutic HGH for goals like fat loss, muscle gain, or recovery in healthy adults. No large randomized trial has tested CJC-1295 plus ipamorelin against placebo or against HGH for those bodybuilding-style endpoints. Everything past the receptor-level mechanism is extrapolation, some of it reasonable, some of it wishful.

What are the side effects, and are they different between the two?

HGH's documented side effects, drawn from decades of clinical use, include fluid retention, joint pain (arthralgia), carpal tunnel-like symptoms, insulin resistance with long-term use, and in rare cases intracranial hypertension, particularly noted in pediatric use ^[1]. These are established through years of monitored, prescribed use with lab follow-up. CJC-1295's side effect profile is thinner because the human data is thinner. The Teichman et al. trial reported injection site reactions and, at some doses, flushing and a tingling sensation, without serious adverse events reported at the doses tested over the trial duration ^[3]. But that was a small trial, not a large safety database. Long-term effects of chronically elevated GH/IGF-1 from repeated GHRH-analogue use, over years, in healthy adults, are simply not established in the literature the way they are for approved HGH therapy. Our CJC-1295 side effects page covers what's reported in the trial data versus what's anecdotal from user reports, and they should not be treated as equally reliable.

How does cost compare between CJC-1295 and HGH?

Prescribed recombinant HGH for diagnosed adult GH deficiency is expensive. Retail cash pricing for brands like Genotropin or Norditropin commonly runs from roughly $1,000 to over $3,000 per month depending on dose and brand, before insurance, and insurance typically requires documented GH deficiency (via stimulation testing) to cover it at all, per manufacturer and pharmacy benefit documentation. CJC-1295, sourced as a research compound, is cheaper per vial, often in the range that puts a month of use well under prescribed HGH costs. That price gap is a major reason it's popular outside clinical settings. But cheaper does not mean equivalent. You're paying less because you're getting a different mechanism, without FDA oversight of manufacturing, and without the clinical monitoring that comes bundled with a legitimate HGH prescription. Cost comparisons that ignore that are comparing two different products, not two prices for the same thing.

Which one is right for someone with diagnosed GH deficiency versus someone looking for anti-aging or bodybuilding effects?

For diagnosed adult GH deficiency (confirmed by stimulation testing and low IGF-1), the standard of care is prescribed recombinant HGH under an endocrinologist, per FDA-approved labeling and monitoring protocols ^[1]. CJC-1295 is not a substitute for this. It has not been studied or approved as a treatment for diagnosed GH deficiency, and relying on an unregulated GHRH analogue instead of a monitored, approved therapy for a real endocrine diagnosis is not something the evidence supports. For the anti-aging, recovery, or body-composition use case, which is where most CJC-1295 interest actually comes from, neither option has strong outcome data. HGH used off-label for anti-aging in people without diagnosed deficiency is itself controversial and not FDA-approved for that use ^[1]. CJC-1295 in this population has even less data behind it, just the endocrine pharmacodynamic trial and a lot of extrapolation from bodybuilding use. If you're going down this road anyway, informed, provider-reviewed sourcing matters more than picking between the two based on marketing claims. CJC-1295 Co reviews sourcing options with this gap in mind, and where a reader wants to move forward, the fulfilling pharmacy partner handles the actual dispensing, not us.

Does CJC-1295 show up on standard growth hormone drug tests?

This is a common question and the honest answer is: it depends on the test, and there isn't good public data specific to CJC-1295 detection windows. Anti-doping labs (WADA-accredited) do test for GHRH and GHRH analogues as a class; GHRH and GH-releasing peptides are listed on the WADA Prohibited List under S2, peptide hormones, growth factors, and related substances ^[7]. So for anyone under a sports testing regime, CJC-1295 is explicitly prohibited, not a loophole around HGH testing. Outside of sports anti-doping contexts, standard medical or workplace drug panels do not screen for GH secretagogues at all; they're not part of routine toxicology panels. That's different from a claim that it's 'undetectable,' which overstates what's actually known.

Frequently asked questions

Can CJC-1295 be used instead of HGH for someone with growth hormone deficiency?

No. Diagnosed adult GH deficiency is treated with FDA-approved recombinant HGH (somatropin) under endocrinologist supervision with IGF-1 monitoring. CJC-1295 has not been approved or studied as a substitute for this and is not standard of care for a confirmed endocrine diagnosis.

Is CJC-1295 the same thing as HGH?

No. HGH is the growth hormone protein itself, injected directly. CJC-1295 is a GHRH analogue that signals your pituitary to release more of its own GH. They raise GH and IGF-1 through different mechanisms, and CJC-1295 only works if your pituitary can still respond to the signal.

Which is more effective, CJC-1295 or HGH?

There's no head-to-head human trial comparing them directly for body composition or performance. HGH has decades of clinical monitoring data for approved indications. CJC-1295 has one small pharmacodynamic trial showing sustained GH/IGF-1 elevation with the DAC version, but no large efficacy trials for anti-aging or fitness goals.

What's the difference between CJC-1295 with DAC and without DAC?

DAC (drug affinity complex) extends CJC-1295's half-life from minutes to roughly 6-8 days by binding albumin, letting one weekly injection sustain elevated GH release. The non-DAC version clears in under 30 minutes and is usually dosed multiple times daily, often paired with ipamorelin timed around natural GH pulses.

Why do people combine CJC-1295 with ipamorelin instead of taking HGH directly?

CJC-1295 and ipamorelin hit different receptors in the GH release pathway (GHRH receptor and ghrelin receptor), which mechanistically can amplify pulsatile GH output. People choose this route over HGH mainly for cost and legal accessibility, not because trials show it outperforms HGH; that comparison hasn't been directly studied.

Is CJC-1295 legal in the United States?

CJC-1295 has no FDA approval for human use and is typically sold labeled for research use only. It occupies a regulatory gray area rather than being an approved or clearly illegal consumer product. Recombinant HGH, by contrast, is FDA-approved but only as a prescription drug for specific diagnosed conditions, and its distribution is restricted under 21 U.S.C. 333(e).

Does CJC-1295 raise IGF-1 as much as HGH does?

In the one published human trial, weekly CJC-1295 with DAC produced dose-dependent, sustained IGF-1 increases over about a week per dose. But it's regulated by your own feedback loops, so it doesn't produce the same reliably titratable IGF-1 elevation that direct HGH dosing does under clinical monitoring.

What are the main side effects of CJC-1295 compared to HGH?

HGH's documented effects from long clinical use include fluid retention, joint pain, and insulin resistance risk with prolonged use. CJC-1295's reported effects, from a small trial, include injection site reactions and flushing; long-term safety data in humans simply doesn't exist at the scale HGH's does.

How much does CJC-1295 cost compared to prescription HGH?

Prescribed HGH brands commonly run $1,000 to over $3,000 per month before insurance. CJC-1295, sourced as a research compound, typically costs substantially less per month, but the lower price reflects a different, unapproved, less-regulated product, not a discount on the same therapy.

Will CJC-1295 show up on a drug test?

GHRH and GHRH analogues are listed under WADA's S2 category of prohibited peptide hormones, so athletes under anti-doping testing are subject to detection and sanction. Standard medical or workplace drug panels don't screen for GH secretagogues at all, so it wouldn't appear there.

Can I switch from HGH to CJC-1295 or vice versa safely?

Anyone on prescribed HGH for a diagnosed condition should not stop or switch without their prescribing physician, since abrupt changes affect IGF-1 levels and metabolic markers being monitored. There's no clinical protocol for switching between the two because they're not established as interchangeable therapies.

Does CJC-1295 without DAC work as well as HGH for muscle gain?

There's no published trial testing CJC-1295 without DAC against HGH for muscle gain. Its short half-life (well under an hour) means its effect is a brief GH pulse rather than a sustained elevation, which is why it's usually stacked with ipamorelin rather than used alone or compared directly to HGH's flat exogenous dosing.

Sources

1. MedlinePlus (NIH), Somatropin Injection: FDA-approved indications, side effects, and off-label anti-aging warnings for recombinant HGH
2. Endocrine Society, Growth Hormone-Releasing Hormone patient resource: Mechanism of GHRH stimulating pituitary GH release
3. Teichman SL, et al., Journal of Clinical Endocrinology & Metabolism (2006), PMID 16352683: CJC-1295 with DAC human trial results: dose-dependent, sustained GH/IGF-1 elevation up to about a week
4. FDA News Release, FDA Approves New Once-Weekly Treatment for Adult Growth Hormone Deficiency (Sogroya), August 28, 2020: FDA approval of a once-weekly long-acting HGH formulation in 2020
5. FDA, Warning Letter to Praxis Compounding Pharmacy (unapproved peptide products): FDA enforcement actions against companies marketing unapproved research-use peptides for human use
6. World Anti-Doping Agency, 2024 Prohibited List (effective January 1, 2024): GHRH and GHRH analogues are listed under S2 as prohibited peptide hormones in sport
7. 21 U.S.C. 333(e), penalties for distribution of human growth hormone: Distribution of human growth hormone for unapproved use carries criminal penalties under federal law